The effect and mechanism of N-(Z)-9-octadecenyl-2-propanesulfonamide in treatment of insulin resistance in type 2 diabetic mice

This study was designed to investigate the therapeutic effect and mechanisms of action of novel compound N-(Z)-9-octadecenyl-2-propanesulfonamide (N15) on type 2 diabetes (T2DM). A mouse model of T2DM was established with multiple injection of streptozotocin (STZ) at a low dose. N15 at different doses (50, 100 and 200 mg·kg^-1·d^-1) and pioglitazone (6 mg·kg^-1·d^-1) were administrated orally for 6 weeks. The level of fasting blood glucose (FBG) and fasting insulin (FIns) were measured in the course of the experiment for insulin resistance index (HOMA-IR). Oral glucose tolerance test (OGTT) and intraperitoneal insulin tolerance test (IPITT) were determined in the treated mice. The expression of Akt, AMPK and Glut4 in liver were analyzed by Western blot. N15 was found to reduce the level of FBG, FIns and HOMA-IR (P < 0.01) and ameliorate the glucose and insulin tolerance (P < 0.01, P < 0.001). Simultaneously the protein expression of p-Akt, p-AMPK and Glut4 was significantly increased in liver by N15 (P < 0.01). These effects were similar to those of pioglitazone (P > 0.05). These results suggested that the novel compound N15 can ameliorate insulin resistance and the potential mechanism may be associated with increased insulin signaling in liver and promotion of phosphatidyl inositol 3 phosphate phosphorylation.